+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID05430698

Phase II Study of PD-1 Antibody Combined with Gemcitabine and Oxaliplatin GEMOX as Postoperative Adjuvant Treatment for Perihilar Cholangiocarcinoma with Lymph Node Metastasis

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-02-09

62

Participants Needed

1

Research Sites

47 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of combining a PD-1 antibody with GEMOX chemotherapy as a postoperative treatment for patients with perihilar cholangiocarcinoma who have cancer spread to their lymph nodes. This exploratory, open-label study seeks to find better options for patients whose prognosis is poorer due to lymph node metastasis after surgery. Participants receive PD-1 antibody infusions and GEMOX chemotherapy, which includes gemcitabine and oxaliplatin. Treatments are given intravenously in cycles lasting three weeks each, with a total of 6 to 8 cycles planned. This combined therapy is given after surgery to assess its potential as an adjuvant treatment. During the study, participants will be closely monitored for disease recurrence and survival, with the main outcome being the relapse-free survival rate at 12 months. Additional assessments include overall survival rates, adverse events, and organ function tests. The study will last several years, including follow-up for up to 60 months to gather long-term data on treatment effects and safety.

CONDITIONS

Brief Title

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Research Team

R

Rui Zhang, PhD

Y

Yanfang Ye

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here